Inventor · disambiguated record
Allard Kaptein
Also filed as: KAPTEIN ALLARD
16 granted patents·27 pending applications·78 citations·filing 1999–2024
92Inventor score
Files withACERTA PHARMA BV34FARROW STUART NEVILLE3MERCK SHARP & DOHME3BARF TJEERD ANDRIES1DE MAN ADRIANUS PETRUS ANTONIUS1
Top patents by PatentIndex Score
43 records- 0196US11771696B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2021·Granted Oct 3, 2023·5 cites·12 claims
- 0295US9949971B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 24, 2018·11 cites·26 claims
- 0394US11654143B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2021·Granted May 23, 2023·3 cites·21 claims
- 0493US10272083B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 30, 2019·14 cites·20 claims
- 0591US11090302B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Aug 17, 2021·4 cites·10 claims
- 0686US12263164B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0786US9718828B2BTK InhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Aug 1, 2017·7 cites·15 claims
- 0884US10328080B2Therapeutic combination of PI3K inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2014·Granted Jun 25, 2019·6 cites·15 claims
- 0984US2024216380A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1082US2025090525A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2024·Application pending·0 cites
- 1180US11166951B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2018·Granted Nov 9, 2021·2 cites·18 claims
- 1274US7399593B1Member of the TNF ligand familySMITHKLINE BEECHAM CORP·Filed 1999·Granted Jul 15, 2008·24 cites·7 claims
- 1373US2021346382A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1469US2021322408A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1569US2019314369A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 1668US11154554B2Therapeutic combinations of a MEK inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Oct 26, 2021·0 cites·4 claims
- 1765US9102676B2MK2 inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted Aug 11, 2015·1 cites·8 claims
- 1864US2019381044A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 1962US2018369244A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 2061US2019209591A1Therapeutic Combinations of a Proteasome Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 2160US8772286B2MK2 inhibitorsBARF TJEERD ANDRIES·Filed 2010·Granted Jul 8, 2014·1 cites·16 claims
- 2260US8216576B2Method for inhibiting binding to B-cell receptorFARROW STUART NEVILLE·Filed 2008·Granted Jul 10, 2012·0 cites·5 claims
- 2359US2018250400A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 2458US2018207154A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 2557US2020069668A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2656US2017231986A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 2756US2015197565A1Novel ligandFARROW STUART NEVILLE·Filed 2014·Application pending·0 cites
- 2856US2020069796A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2955US2017035881A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 3055US2019008869A1Therapeutic Combinations of an Antifolate and a BTK InhibitorACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 3154US8784814B2Method for inhibiting binding to B-cell receptorFARROW STUART NEVILLE·Filed 2012·Granted Jul 22, 2014·0 cites·7 claims
- 3254US2017143712A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 3354US2017231995A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 3454US2017071962A1Therapeutic Combinations of a Proteasome Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 3554US2019008859A1Therapeutic Combinations of a MEK Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 3653US2019374543A1Therapeutic Combinations of an Antifolate and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3752US2019358235A1Therapeutic Combination of a PI3K Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3851US2017224819A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 3950US10858364B2Imidazopyrazine inhibitors of Bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2017·Granted Dec 8, 2020·0 cites·14 claims
- 4044US2016159800A1Mk2 inhibitorsMERCK SHARP & DOHME·Filed 2015·Application pending·0 cites
- 4144US2014221333A1Btk inhibitorsDE MAN ADRIANUS PETRUS ANTONIUS·Filed 2012·Application pending·0 cites
- 4242US2017239351A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4337US2019376971A1Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine KinaseACERTA PHARMA BV·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →